Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESTA NASDAQ:EYE NASDAQ:MDXG NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$71.22-1.1%$65.27$33.30▼$83.31$2.09B1.12517,695 shs78,980 shsEYENational Vision$22.93+0.4%$25.74$16.61▼$30.02$1.84B1.181.31 million shs108,045 shsMDXGMiMedx Group$3.67-0.7%$4.02$3.03▼$7.99$545.90M1.461.25 million shs255,741 shsNVCRNovoCure$17.54+4.2%$12.41$9.82▼$20.06$2.03B0.91.81 million shs596,429 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-3.48%+4.95%+22.06%+4.71%+116.50%EYENational Vision+0.71%-1.68%-5.62%-21.06%+46.70%MDXGMiMedx Group+0.82%+9.82%-4.40%-28.35%-47.08%NVCRNovoCure+2.00%+10.65%+62.61%+65.98%+1.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$71.22-1.1%$65.27$33.30▼$83.31$2.09B1.12517,695 shs78,980 shsEYENational Vision$22.93+0.4%$25.74$16.61▼$30.02$1.84B1.181.31 million shs108,045 shsMDXGMiMedx Group$3.67-0.7%$4.02$3.03▼$7.99$545.90M1.461.25 million shs255,741 shsNVCRNovoCure$17.54+4.2%$12.41$9.82▼$20.06$2.03B0.91.81 million shs596,429 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-3.48%+4.95%+22.06%+4.71%+116.50%EYENational Vision+0.71%-1.68%-5.62%-21.06%+46.70%MDXGMiMedx Group+0.82%+9.82%-4.40%-28.35%-47.08%NVCRNovoCure+2.00%+10.65%+62.61%+65.98%+1.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESTAEstablishment Labs 2.63Moderate Buy$87.1422.35% UpsideEYENational Vision 2.54Moderate Buy$32.0839.90% UpsideMDXGMiMedx Group 2.71Moderate Buy$8.50131.92% UpsideNVCRNovoCure 2.38Hold$27.2955.61% UpsideCurrent Analyst Ratings BreakdownLatest MDXG, ESTA, NVCR, and EYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$88.00 ➝ $90.005/6/2026ESTAEstablishment Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/4/2026MDXGMiMedx Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/4/2026NVCRNovoCure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$13.50 ➝ $17.005/1/2026NVCRNovoCure EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/30/2026MDXGMiMedx Group Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$7.00 ➝ $6.004/29/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/21/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026MDXGMiMedx Group Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.00 ➝ $7.004/17/2026MDXGMiMedx Group Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $7.004/16/2026NVCRNovoCure WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESTAEstablishment Labs$211.08M9.92N/AN/A$0.81 per share87.93EYENational Vision$1.99B0.92$1.81 per share12.66$10.96 per share2.09MDXGMiMedx Group$418.63M1.30$0.55 per share6.61$1.63 per share2.25NVCRNovoCure$674.41M3.01N/AN/A$2.86 per share6.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESTAEstablishment Labs-$51.06M-$1.74N/A173.72N/A-19.05%-202.78%-12.39%N/AEYENational Vision$29.60M$0.3762.0824.391.711.49%5.15%2.22%5/13/2026 (Confirmed)MDXGMiMedx Group$48.58M$0.2018.3361.08N/A7.88%21.03%15.92%N/ANVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)Latest MDXG, ESTA, NVCR, and EYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026EYENational Vision$0.43N/AN/AN/A$545.09 millionN/A5/6/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million4/29/2026Q1 2026MDXGMiMedx Group-$0.07-$0.05+$0.02-$0.07$65.80 million$58.99 million3/4/2026Q4 2025EYENational Vision$0.06$0.15+$0.09$0.04$495.26 million$503.41 million2/26/2026Q4 2025NVCRNovoCure-$0.41-$0.22+$0.19-$0.22$174.40 million$174.35 million2/25/2026Q4 2025MDXGMiMedx Group$0.09$0.14+$0.05$0.10$106.78 million$118.10 million2/24/2026Q4 2025ESTAEstablishment Labs-$0.22-$0.09+$0.13-$0.09$63.80 million$64.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESTAEstablishment LabsN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESTAEstablishment Labs10.513.042.00EYENational Vision0.260.550.33MDXGMiMedx Group0.075.394.81NVCRNovoCure0.712.902.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESTAEstablishment Labs72.91%EYENational VisionN/AMDXGMiMedx Group79.15%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipESTAEstablishment Labs9.99%EYENational Vision2.70%MDXGMiMedx Group1.70%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESTAEstablishment Labs1,00429.39 million26.45 millionOptionableEYENational Vision13,13880.12 million77.95 millionOptionableMDXGMiMedx Group870148.95 million146.41 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionableMDXG, ESTA, NVCR, and EYE HeadlinesRecent News About These CompaniesHC Wainwright Estimates NovoCure's Q2 Earnings (NASDAQ:NVCR)May 5 at 8:32 AM | marketbeat.comNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00 at Wells Fargo & CompanyMay 4, 2026 | marketbeat.comStocks with rising relative price strength: NovocureMay 4, 2026 | msn.comInternational Markets and NovoCure (NVCR): A Deep Dive for InvestorsMay 4, 2026 | zacks.comNovoCure (NASDAQ:NVCR) Shares Up 6.8% - Here's WhyMay 3, 2026 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 2, 2026 | finance.yahoo.comNovoCure (NASDAQ:NVCR) Trading 6.8% Higher - Should You Buy?May 1, 2026 | marketbeat.comNovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer YetMay 1, 2026 | seekingalpha.comNovoCure: Q1 Earnings SnapshotMay 1, 2026 | chron.comNovocure jumps after raising FY26 sales outlook, Q1 revenue beatMay 1, 2026 | seekingalpha.comTwo medical stocks skyrocket after demolishing views — and one is about to break outMay 1, 2026 | msn.comNovoCure (NVCR) Q1 2026 Earnings TranscriptMay 1, 2026 | finance.yahoo.comWhy NovoCure Limited’s (NVCR) Stock Is Up 19.53%May 1, 2026 | aaii.comANovoCure (NASDAQ:NVCR) Announces Earnings ResultsApril 30, 2026 | marketbeat.comNovoCure Limited (NVCR) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy?April 30, 2026 | marketbeat.comNovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesApril 30, 2026 | zacks.comNovoCure Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comNovoCure Limited 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by AnalystsApril 25, 2026 | marketbeat.comNovoCure (NVCR) to Release Quarterly Earnings on ThursdayApril 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026East West Bancorp: Confronting the Risks With Record Results By Peter Frank | April 10, 2026Prologis Q1 2026: Data Centers Steal the ShowBy Chris Markoch | April 18, 2026Does Cheesecake Factory Stock Have Any Upside Left on the Menu?By Jennifer Ryan Woods | April 27, 2026Did Qualcomm Just Put Apple in Check?By Jeffrey Neal Johnson | April 28, 2026MDXG, ESTA, NVCR, and EYE Company DescriptionsEstablishment Labs NASDAQ:ESTA$71.22 -0.81 (-1.12%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.National Vision NASDAQ:EYE$22.93 +0.10 (+0.43%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.MiMedx Group NASDAQ:MDXG$3.66 -0.03 (-0.68%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.NovoCure NASDAQ:NVCR$17.54 +0.71 (+4.19%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
